Harvard Bioscience, Inc. to Continue Using Its Name

Apr 10, 2001, 01:00 ET from Harvard Bioscience, Inc.

    HOLLISTON, Mass., April 10 /PRNewswire/ -- Harvard Bioscience, Inc.
 (Nasdaq:   HBIO) today reported that the United States District Court, District
 of Massachusetts has denied Harvard University's request for a preliminary
 injunction prohibiting Harvard Bioscience, Inc. from using the name "Harvard."
 The Court did issue an order that directs Harvard Bioscience not to use the
 "Harvard" name in the color crimson, or in a font similar to the font used by
 the University.
     "The Harvard Apparatus and Harvard Bioscience names have been in use for
 at least a hundred years and twenty years, respectively", commented Chane
 Graziano, CEO of Harvard Bioscience,  "and are well known among researchers
 around the world.  We do not expect that complying with this order by the
 Court will have any material impact on our business, financial condition or
 results of operations."
     Harvard Bioscience is a global developer, manufacturer and marketer of
 innovative, enabling tools in drug discovery research at pharmaceutical and
 biotechnology companies, universities and government laboratories.  HBIO sells
 approximately 10,000 products to thousands of researchers in over 60 countries
 though its 1,000 page catalog, and through its distributors, the most notable
 of which is AP Biotech.  HBIO has sales and manufacturing operations in the
 United States, the United Kingdom, and Germany with sales facilities in France
 and Canada.
     The statements made in this press release that are not statements of
 historical fact are forward-looking statements within the meaning of Section
 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
 Act of 1934.  These statements involve known and unknown risks, uncertainties
 and other factors that may cause the Company's actual results, performance or
 achievements to be materially different from any future results, performance
 or achievements expressed or implied by the forward-looking statements.
 Forward-looking statements contained in this press release include, but are
 not limited to, statements about the Company's expectations as to the impact
 on its business, financial and results of operations resulting from complying
 with the Court's order, and the Company's plans, objectives and intentions
 contained in this press release that are not historical facts.  The Company
 cautions that the denial of a preliminary injunction is not a final decision
 on the merits of the case and that the Court's denial of the preliminary
 injunction may not be indicative of the Company's actual likelihood of success
 on the merits.  Other factors that may cause the Company's actual results to
 differ materially from those in the forward looking statements include those
 set forth under the heading "Important Factors That May Affect Future
 Operating Results" in the Companies filing on Form 10-K for the fiscal year
 ended December 31, 2000, as well as other risks described in the Company's
 public filings or factors, if any, of which the Company is not currently
 aware.  The Company may not update these forward-looking statements, even
 though its situation may change in the future, unless it has obligations under
 the Federal securities laws to update and disclose material developments
 related to previously disclosed information.
     For investor inquiries, please call (508) 893-8066.   Press releases may
 be found on our web site, http://www.harvardbioscience.com.
 
 

SOURCE Harvard Bioscience, Inc.
    HOLLISTON, Mass., April 10 /PRNewswire/ -- Harvard Bioscience, Inc.
 (Nasdaq:   HBIO) today reported that the United States District Court, District
 of Massachusetts has denied Harvard University's request for a preliminary
 injunction prohibiting Harvard Bioscience, Inc. from using the name "Harvard."
 The Court did issue an order that directs Harvard Bioscience not to use the
 "Harvard" name in the color crimson, or in a font similar to the font used by
 the University.
     "The Harvard Apparatus and Harvard Bioscience names have been in use for
 at least a hundred years and twenty years, respectively", commented Chane
 Graziano, CEO of Harvard Bioscience,  "and are well known among researchers
 around the world.  We do not expect that complying with this order by the
 Court will have any material impact on our business, financial condition or
 results of operations."
     Harvard Bioscience is a global developer, manufacturer and marketer of
 innovative, enabling tools in drug discovery research at pharmaceutical and
 biotechnology companies, universities and government laboratories.  HBIO sells
 approximately 10,000 products to thousands of researchers in over 60 countries
 though its 1,000 page catalog, and through its distributors, the most notable
 of which is AP Biotech.  HBIO has sales and manufacturing operations in the
 United States, the United Kingdom, and Germany with sales facilities in France
 and Canada.
     The statements made in this press release that are not statements of
 historical fact are forward-looking statements within the meaning of Section
 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
 Act of 1934.  These statements involve known and unknown risks, uncertainties
 and other factors that may cause the Company's actual results, performance or
 achievements to be materially different from any future results, performance
 or achievements expressed or implied by the forward-looking statements.
 Forward-looking statements contained in this press release include, but are
 not limited to, statements about the Company's expectations as to the impact
 on its business, financial and results of operations resulting from complying
 with the Court's order, and the Company's plans, objectives and intentions
 contained in this press release that are not historical facts.  The Company
 cautions that the denial of a preliminary injunction is not a final decision
 on the merits of the case and that the Court's denial of the preliminary
 injunction may not be indicative of the Company's actual likelihood of success
 on the merits.  Other factors that may cause the Company's actual results to
 differ materially from those in the forward looking statements include those
 set forth under the heading "Important Factors That May Affect Future
 Operating Results" in the Companies filing on Form 10-K for the fiscal year
 ended December 31, 2000, as well as other risks described in the Company's
 public filings or factors, if any, of which the Company is not currently
 aware.  The Company may not update these forward-looking statements, even
 though its situation may change in the future, unless it has obligations under
 the Federal securities laws to update and disclose material developments
 related to previously disclosed information.
     For investor inquiries, please call (508) 893-8066.   Press releases may
 be found on our web site, http://www.harvardbioscience.com.
 
 SOURCE  Harvard Bioscience, Inc.